Which is better, ipamorelin or MK-677 (ibutamoren)?
Both are graded human RCT, but MK-677 is far better characterized: it has randomized trials of body composition, including a 2 year trial in 65 older adults, while ipamorelin's one randomized trial tested intravenous dosing after bowel surgery and found no benefit, and no randomized trial has tested it for the uses it is sold for. But that evidence shows modest lean mass gain with no functional benefit and real harms, and FDA keeps MK-677 in both 503A and 503B Category 2 over the heart failure signal, while ipamorelin's 503A nomination was withdrawn after its own Category 2 listing. Neither has a lawful US access path, so there is no scenario where one is a recommended choice over the other. [1] [2] [4] [8] [9] [10] [12]
How do ipamorelin and MK-677 (ibutamoren) compare?
| Dimension | Ipamorelin | MK-677 (ibutamoren) |
|---|---|---|
| Molecule and route [1] [6] | Synthetic pentapeptide, given by injection (subcutaneous as sold; intravenous in the only human trial). | Non peptide small molecule taken orally once daily; its half life supports daily dosing. |
| Evidence grade [1] [2] [3] [4] [5] [7] [12] | Human RCT: one randomized, double blind, placebo controlled trial (117 adults after bowel surgery, intravenous) found no benefit. For GH related uses the data are one infusion study in healthy men plus animal work: selective GH release in rats and pigs, bone growth in rats. | Human RCT: several randomized placebo controlled trials from 4 weeks to 2 years in older adults, obese men, and people with Alzheimer disease. |
| Human body composition data [1] [4] [5] | None published; the only human RCT measured recovery of bowel function after surgery and found no significant benefit. | Two years of 25 mg daily in 65 adults aged 60 to 81: fat free mass up about 1.1 kg versus placebo, no gain in strength or function. Eight weeks in 24 obese men: fat free mass up about 3 kg, no fat loss. |
| Hormonal selectivity [2] [6] | In animals it did not raise ACTH, cortisol, or prolactin even at 200 times the GH ED50. | Transient rises in cortisol and prolactin reported; raises 24 hour GH and IGF-1 into the young adult range in older people. |
| Safety signals [1] [4] [8] [10] | No signal versus placebo over 7 days of intravenous dosing; long term effects untested. FDA cited immunogenicity from aggregation and impurities. | Increased appetite, edema, muscle pain, higher fasting glucose and reduced insulin sensitivity over 2 years; a hip fracture trial was terminated early for a possible congestive heart failure signal. |
| Literature dosing [1] [4] [6] | Not established for GH use; the human trial used 0.03 mg/kg intravenously twice daily for up to 7 days. | Trials used 25 mg orally once daily, with 2 mg and 50 mg arms in early studies. Research doses only. |
| FDA compounding status [9] [10] [11] | 503A Category 2 in September 2023; 503A nominations withdrawn in 2024, now listed as a withdrawn 503A nomination. Ipamorelin acetate remains in 503B Category 2. | 503B Category 2 since December 2022 and 503A Category 2 since September 2023, citing the heart failure risk; still in both as of April 2026. It also may not be sold as a dietary supplement. |
| Note: Both are prohibited at all times under WADA section S2. | ||
Evidence grade and regulatory status
Pulled from each peptide’s own record, so it stays in step with the peptide pages.
| Attribute | Ipamorelin | MK-677 (ibutamoren) |
|---|---|---|
| Class | Synthetic pentapeptide growth hormone secretagogue; selective agonist at the ghrelin receptor (GHS-R1a) | Oral non peptide growth hormone secretagogue (small molecule ghrelin receptor agonist) |
| What it is | Growth hormone releaser acting on the hunger hormone (ghrelin) receptor; its one randomized placebo controlled trial, after bowel surgery, found no benefit. | Oral ghrelin mimetic with real RCTs: raises IGF-1 and lean mass modestly, raises glucose and appetite, a heart failure signal stopped development. Not approved. |
| Evidence | Evidence: Human RCT evidence | Evidence: Human RCT evidence |
| FDA status | Regulatory: Nomination withdrawn | Regulatory: Not eligible for compounding |
| Compounding | Not FDA approved for any use. Ipamorelin was nominated for the 503A bulks list and placed in Category 2. FDA cited immunogenicity risk from aggregation or peptide related impurities, unnatural amino acids that complicate characterization, and a published report of serious adverse events, including a death, when it was given intravenously. On October 29, 2024 the Pharmacy Compounding Advisory Committee voted against adding ipamorelin free base or ipamorelin acetate to the 503A bulks list. FDA now lists ipamorelin acetate among 503A nominations withdrawn by the nominators, which puts it in no 503A category and outside FDA's interim policy. Ipamorelin acetate also remains in 503B Category 2, added September 29, 2023. It is not on the 503A bulks list, so as of the last verification date neither 503A pharmacies nor 503B outsourcing facilities have a federal basis to compound it. | Not FDA approved for any use. FDA placed ibutamoren mesylate in 503B Category 2 on December 29, 2022 and in 503A Category 2 on September 29, 2023, citing the potential for congestive heart failure based on the terminated hip fracture trial. As of the FDA page current to April 22, 2026, it remains in both categories, so no licensed pharmacy or outsourcing facility can lawfully compound it. It was not among the substances withdrawn from Category 2 in April 2026. It is widely sold online as a research chemical or mislabeled supplement. |
| WADA | WADA: WADA prohibited | WADA: WADA prohibited |
| Routes | Subcutaneous injection (as sold, no human pharmacokinetic publication), Intravenous infusion (human ileus trial), Intranasal (anti-doping metabolite study only) | Oral capsule or tablet, once daily (all trials and as sold) |
| Typical cost | Not available through licensed channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. | Not available through licensed US channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. |
| Last verified |
Has ipamorelin been tested directly against MK-677 (ibutamoren)?
No published trial has compared ipamorelin and MK-677 (ibutamoren) directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.
What do ipamorelin and MK-677 (ibutamoren) cost?
| Dimension | Ipamorelin | MK-677 (ibutamoren) |
|---|---|---|
| Typical cost | Not available through licensed channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. | Not available through licensed US channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. |
| Price detail | Ipamorelin price by channel | Price index in progress |
Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.
What's actually offered, what that means for you, and what to check if you're going ahead anyway: see the Ipamorelin page and the MK-677 (ibutamoren) page.
Frequently asked questions
Do ipamorelin and MK-677 work the same way?
Yes, both activate the ghrelin receptor (GHS-R1a) to release growth hormone. The difference is form: ipamorelin is an injected peptide, MK-677 is an oral small molecule taken once daily. [2] [6]
Which has better human evidence?
MK-677, by a wide margin. It has randomized trials up to 2 years long, including one where 25 mg daily raised fat free mass by about 1.1 kg versus placebo in older adults. Ipamorelin has no human trial measuring IGF-1 or body composition; its human growth hormone data are one small IV pharmacology study showing growth hormone release in healthy men. [1] [4] [12]
Does MK-677 build muscle strength?
Not in the best trial. The 2 year study found a lean mass gain without any improvement in strength or physical function, along with higher fasting glucose and reduced insulin sensitivity. [4]
Why does FDA consider MK-677 a safety risk?
A phase 2b trial in hip fracture patients was stopped early because of a possible congestive heart failure signal, and FDA cited that when it placed ibutamoren in both the 503A and 503B Category 2 lists. [8] [9]
Can I get either one legally?
No. Neither is FDA approved, MK-677 is in Category 2 for both pharmacy types, and ipamorelin has no active nomination or bulks list entry, so licensed pharmacies cannot compound either. Products sold as research chemicals or supplements are not lawful for human use. [9] [10]
Conditions studied
From the blog
- Ipamorelin side effects and benefits: what studies show
Ipamorelin side effects in its one human trial matched placebo, but FDA flags serious events with IV use. Claimed benefits for muscle, fat loss, and sleep are untested. Not FDA approved.
- Peptide stacks: what each common component has shown alone
No trial has tested a multi-peptide stack for muscle growth or fat loss. Nine common stack components ranked by their own human evidence, legal status, and WADA status. No protocols.
- Peptides for muscle growth, ranked by human evidence
MK-677, sermorelin, tesamorelin, CJC-1295, IGF-1 LR3, and more ranked by human evidence. None is approved for muscle growth, and all ten are banned in tested sport.
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014PubMed 25331030, 2014
- [2]Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998PubMed 9849822, 1998
- [3]Johansen PB et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res 1999PubMed 10373343, 1999
- [4]Nass R et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 2008PubMed 18981485, 2008
- [5]Svensson J et al. Two-month treatment of obese subjects with the oral GH secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab 1998PubMed 9467542, 1998
- [6]Chapman IM et al. Stimulation of the GH-IGF-I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab 1996PubMed 8954023, 1996
- [7]Sevigny JJ et al. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology 2008PubMed 19015485, 2008
- [8]Adunsky A et al. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr 2011PubMed 21067829, 2011
- [9]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list, content current as of April 22, 2026)FDA
- [10]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (503A bulks list, Category 1, 2, and 3 lists, and withdrawn nominations)FDA
- [11]WADA Prohibited List, section S2 (growth hormone secretagogues, including ipamorelin and ibutamoren)WADA
- [12]Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res 1999PubMed 10496658, 1999
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 30). Ipamorelin vs MK-677 (ibutamoren): evidence, cost, and legality. https://peptideagent.ai/compare/ipamorelin-vs-mk-677- HTML link
<a href="https://peptideagent.ai/compare/ipamorelin-vs-mk-677">Ipamorelin vs MK-677 (ibutamoren): evidence, cost, and legality</a>, PeptideAgent, updated September 30, 2026.